Thesis: competition, analyst: white-diamond-research, sector: pharma.
see below
More ... latest change: 2026-02-28
White Diamond Research published on Aytu Biopharma (NASDAQ: AYTU — $13 million), a pharmaceutical company focused on ADHD treatments. White Diamond alleged that starting in September 2025, the company’s ADHD portfolio “will be completely replaced by generics from Teva.” 2026-01-30 USD 2.6
Last updated: 2026-03-07 by automated standardization process
last updated: